KRAS and pancreatic neoplasm: In another report on MEKi synthetic lethalities, Sulahian et al. [122] performed a genome-scale CRISPR/Cas9 screen in the presence of trametinib that identified SHOC2 as a synthetic lethality when combined with MEK inhibition in KRAS-mutant lung and pancreas cancers.